Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06805617
Title A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers (I-MAC)
Acronym I-MAC
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Glenn J. Hanna
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.